ACCEL-SILDENAFIL 100 MG
SILDENAFIL (SILDENAFIL CITRATE) : 100 MG · DIN 02479826 · ACCEL PHARMA INC
Health Canada status: MARKETED
What is ACCEL-SILDENAFIL?
ACCEL-SILDENAFIL 100 MG contains SILDENAFIL (SILDENAFIL CITRATE) : 100 MG. It is listed in the Health Canada Drug Product Database under DIN 02479826, held by ACCEL PHARMA INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 15-Aug-2019. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is ACCEL-SILDENAFIL used for?
Treatment of erectile dysfunction, which is the inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02479826 |
|---|---|
| Brand name | ACCEL-SILDENAFIL |
| Generic / active ingredient | SILDENAFIL (SILDENAFIL CITRATE) : 100 MG |
| Manufacturer | ACCEL PHARMA INC |
| Strength | 100 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | G04BE03 SILDENAFIL |
| AHFS class | 24:12.12 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 15-Aug-2019 |
| Original market date | 2019-08-15 00:00:00 |
How is it administered?
For most patients, 50 mg approx. 1 hour before sexual activity. Range 25-100 mg. Max once daily. Starting dose of 25 mg for elderly (>65), hepatic or severe renal impairment, or certain CYP3A4 inhibitors.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store at 15-30°C (implied by standard House Standard/cGMP context, though specific text section was cut off).
How is it supplied?
Not explicitly detailed in provided text (mentions 25 mg, 50 mg, 100 mg strengths).
Contraindications
Co-administration with nitrates (organic nitrates in any form) or guanylate cyclase stimulators (e.g., riociguat). Hypersensitivity to components. Previous episode of NAION.
Warnings and precautions
Potential cardiac risk of sexual activity. Caution in patients with recent MI, stroke, or arrhythmia. Risk of sudden vision/hearing loss. Potential for priapism. Vasodilatory effects.
What can be used instead?
Other Canadian products sharing ATC code G04BE03 SILDENAFIL. 42 of 127 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACCEL-SILDENAFIL | 25 MG | TABLET | ACCEL PHARMA INC | MARKETED | DIN 02479796 |
| ACCEL-SILDENAFIL | 50 MG | TABLET | ACCEL PHARMA INC | MARKETED | DIN 02479818 |
| AG-SILDENAFIL TABLETS | 100 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02503344 |
| APO-SILDENAFIL | 100 MG | TABLET | APOTEX INC | MARKETED | DIN 02248203 |
| APO-SILDENAFIL | 25 MG | TABLET | APOTEX INC | MARKETED | DIN 02248201 |
| APO-SILDENAFIL | 50 MG | TABLET | APOTEX INC | MARKETED | DIN 02248202 |
| AURO-SILDENAFIL | 100 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02414384 |
| AURO-SILDENAFIL | 25 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02414368 |
| AURO-SILDENAFIL | 50 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02414376 |
| BIO-SILDENAFIL | 100 MG | TABLET | BIOMED PHARMA | MARKETED | DIN 02480980 |
Who else supplies SILDENAFIL worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. SILDENAFIL appears in 3124 registered pack listings across 13 markets, published on 11 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.